Clinical trials: Congenital Antithrombin Deficiency
Antithrombin III Deficiency, Extracorporeal Membrane Oxygenation Complication
Prospective Investigation of Antithrombin III Deficiency in Adult Patients With ECMO
There are publications showing a decrease in Antithrombin III levels of continuous flow and routine heparin therapy in adult patients undergoing Extracorporeal Membrane Oxygenation (ECMO) however, there is not enough data.
- Trial name
- NCT04879550
- Testing
- Antithrombin III
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
Antithrombin III Deficiency
Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate
To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate in the treatment of subjects with congenital AT-III deficiency.
- Trial name
- NCT00319228
- Testing
- Plasma-derived AT-III concentrate
- Volunteers
- 3 people
- Sponsor
- Instituto Grifols, S.A.
Antithrombin III Deficiency
Atenativ Effect on Uterine Blood Flow and Preeclampsia
The study will be an open controlled pilot study of 6 patients with early-onset severe preeclampsia. Patients will receive Atenativ in addition to conventional therapy The patients will be followed up within the study until three…
- Trial name
- NCT02278575
- Testing
- Atenativ
- Where
- Sweden
- Sponsor
- Vastra Gotaland Region
Antithrombin III Deficiency
Belgian Antithrombin Deficiency Registry
Inherited antithrombin deficiency is a rare autosomal dominant disorder that predisposes to the development of venous thromboembolism, even at young age.
- Trial name
- NCT05891899
- Testing
- observation
- Where
- Belgium
- Volunteers
- 1,000 people
- Sponsor
- Universitair Ziekenhuis Brussel
Antithrombin III Deficiency, Covid19
Antithrombin III in Infectious Disease Caused by COVID-19
The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.
- Trial name
- NCT04899232
- Testing
- Antithrombin III
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Enrique Ginzburg
Antithrombin Deficiency, Congenital
Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.
Patients with hereditary antithrombin (AT) deficiency are at increased risk of venous thrombosis and pulmonary embolism, particularly during certain high risk procedures.
- Trial name
- rhAT (NCT00056550)
- Testing
- Recombinant Human Antithrombin (rhAT)
- Where
- 11 sites in United States, France and 4 more
- Volunteers
- 14 people
- Sponsor
- rEVO Biologics
Congenital Antithrombin Deficiency
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
The goal of this study is to assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under when they receive Atenativ for surgical…
- Trial name
- NCT04918173
- Testing
- Atenativ
- Where
- 30 sites in United States, Armenia and 12 more
- Volunteers
- 38 people
- Sponsor
- Octapharma
Antithrombin III Deficiency
Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery
Patients with hereditary antithrombin deficiency are at increased risk of venous thrombosis and pulmonary embolism, particularly during certain high risk procedures.
- Trial name
- NCT00110513
- Testing
- Recombinant human antithrombin (rhAT)
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 18 people
- Sponsor
- rEVO Biologics
Congenital Heart Diseases, Conotruncal Defects
"Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects"
The objective of the study is to investigate congenital disorders of glycosylation in congenital heart diseases without a clear molecular or genetic basis.
- Conditions
- Congenital Heart Diseases, Conotruncal Defects, Congenital Disorder of Glycosylation, Antithrombin III Deficiency
- Trial name
- (CARDIoG) (NCT02503267)
- Testing
- none intervention
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Acquired Antithrombin Deficiency
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating…
- Trial name
- NCT06096116
- Testing
- Human plasma derived antithrombin
- Where
- 27 sites in United States, Austria and 8 more
- Volunteers
- 120 people
- Sponsor
- Octapharma
Congenital Antithrombin Deficiency
A Study of KW-3357 in Congenital Antithrombin Deficiency
The aim of this study is to determine the pharmacokinetics, safety and tolerability of KW-3357 in asymptomatic subjects with congenital antithrombin deficiency.
- Trial name
- NCT00938288
- Testing
- KW-3357
- Where
- 8 sites in Germany, Sweden and 1 more
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.